Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review
<h3>Purpose</h3><p dir="ltr">Statins are widely prescribed for cardiovascular diseases (CVD) prevention; however, a significant proportion of users discontinue the medication for various reasons. This review aimed to determine the prevalence of statin therapy discontinuat...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513537473249280 |
|---|---|
| author | Shahd A. Ageeb (22047824) |
| author2 | Alaa Abdelmoghith (22047827) Hager ElGeed (20642703) Ahmed Awaisu (5121473) Abdulmoniem ElMansor (22047830) Yaw B. Owusu (22047833) |
| author2_role | author author author author author |
| author_facet | Shahd A. Ageeb (22047824) Alaa Abdelmoghith (22047827) Hager ElGeed (20642703) Ahmed Awaisu (5121473) Abdulmoniem ElMansor (22047830) Yaw B. Owusu (22047833) |
| author_role | author |
| dc.creator.none.fl_str_mv | Shahd A. Ageeb (22047824) Alaa Abdelmoghith (22047827) Hager ElGeed (20642703) Ahmed Awaisu (5121473) Abdulmoniem ElMansor (22047830) Yaw B. Owusu (22047833) |
| dc.date.none.fl_str_mv | 2024-08-13T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/pds.5879 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Prevalence_Associated_Risk_Factors_and_Adverse_Cardiovascular_Outcomes_of_Statins_Discontinuation_A_Systematic_Review/29900675 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Public health Statins Cardiovascular disease (CVD) All-cause mortality Risk factors Smoking Uninsured patients Ethnic disparities |
| dc.title.none.fl_str_mv | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Purpose</h3><p dir="ltr">Statins are widely prescribed for cardiovascular diseases (CVD) prevention; however, a significant proportion of users discontinue the medication for various reasons. This review aimed to determine the prevalence of statin therapy discontinuation, its associated factors, and adverse cardiovascular outcomes within the first year of discontinuation.</p><h3>Methods</h3><p dir="ltr">The PubMed, EMBASE, ScienceDirect, SCOPUS, and Google Scholar databases were systematically searched from their inception to December 2022. Manual searches were also conducted on the bibliographies of relevant articles. Studies were included for qualitative data synthesis and assessed for methodological quality.</p><h3>Results</h3><p dir="ltr">Fifty‐two studies, predominantly cohort studies (n = 38), involving 4 277 061 participants were included. The prevalence of statin discontinuation within the first year of statin initiation ranged from 0.8% to 70.5%, which was higher for primary prevention indications. Factors frequently associated with an increased likelihood of statin discontinuation included male sex, nonWhite ethnicity, smoking status, and being uninsured. Conversely, discontinuation was less likely in patients with CVD who received secondary prevention statin therapy and in patients with polypharmacy. Furthermore, age showed diverse and inconsistent relationships with statin discontinuation among various age categories. Five studies that reported the cardiovascular risk of statin discontinuation within the first year of initiation showed significantly increased risk of discontinuation, including all‐cause mortality (hazard ratio: 1.36–3.65).</p><h3>Conclusion</h3><p dir="ltr">Our findings indicate a high prevalence of statin discontinuation and an increased likelihood of adverse cardiovascular outcomes within the first year of discontinuation, despite wide variability across published studies. This review highlights the importance of addressing the modifiable risk factors associated with statin discontinuation, such as smoking and lack of insurance coverage.</p><h2>Other Information</h2><p dir="ltr">Published in: Pharmacoepidemiology and Drug Safety<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/pds.5879" target="_blank">https://dx.doi.org/10.1002/pds.5879</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_91017046b1b7b23bdf05ce06053d6918 |
| identifier_str_mv | 10.1002/pds.5879 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29900675 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic ReviewShahd A. Ageeb (22047824)Alaa Abdelmoghith (22047827)Hager ElGeed (20642703)Ahmed Awaisu (5121473)Abdulmoniem ElMansor (22047830)Yaw B. Owusu (22047833)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyPublic healthStatinsCardiovascular disease (CVD)All-cause mortalityRisk factorsSmokingUninsured patientsEthnic disparities<h3>Purpose</h3><p dir="ltr">Statins are widely prescribed for cardiovascular diseases (CVD) prevention; however, a significant proportion of users discontinue the medication for various reasons. This review aimed to determine the prevalence of statin therapy discontinuation, its associated factors, and adverse cardiovascular outcomes within the first year of discontinuation.</p><h3>Methods</h3><p dir="ltr">The PubMed, EMBASE, ScienceDirect, SCOPUS, and Google Scholar databases were systematically searched from their inception to December 2022. Manual searches were also conducted on the bibliographies of relevant articles. Studies were included for qualitative data synthesis and assessed for methodological quality.</p><h3>Results</h3><p dir="ltr">Fifty‐two studies, predominantly cohort studies (n = 38), involving 4 277 061 participants were included. The prevalence of statin discontinuation within the first year of statin initiation ranged from 0.8% to 70.5%, which was higher for primary prevention indications. Factors frequently associated with an increased likelihood of statin discontinuation included male sex, nonWhite ethnicity, smoking status, and being uninsured. Conversely, discontinuation was less likely in patients with CVD who received secondary prevention statin therapy and in patients with polypharmacy. Furthermore, age showed diverse and inconsistent relationships with statin discontinuation among various age categories. Five studies that reported the cardiovascular risk of statin discontinuation within the first year of initiation showed significantly increased risk of discontinuation, including all‐cause mortality (hazard ratio: 1.36–3.65).</p><h3>Conclusion</h3><p dir="ltr">Our findings indicate a high prevalence of statin discontinuation and an increased likelihood of adverse cardiovascular outcomes within the first year of discontinuation, despite wide variability across published studies. This review highlights the importance of addressing the modifiable risk factors associated with statin discontinuation, such as smoking and lack of insurance coverage.</p><h2>Other Information</h2><p dir="ltr">Published in: Pharmacoepidemiology and Drug Safety<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/pds.5879" target="_blank">https://dx.doi.org/10.1002/pds.5879</a></p>2024-08-13T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/pds.5879https://figshare.com/articles/journal_contribution/Prevalence_Associated_Risk_Factors_and_Adverse_Cardiovascular_Outcomes_of_Statins_Discontinuation_A_Systematic_Review/29900675CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/299006752024-08-13T09:00:00Z |
| spellingShingle | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review Shahd A. Ageeb (22047824) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Public health Statins Cardiovascular disease (CVD) All-cause mortality Risk factors Smoking Uninsured patients Ethnic disparities |
| status_str | publishedVersion |
| title | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| title_full | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| title_fullStr | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| title_full_unstemmed | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| title_short | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| title_sort | Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Health sciences Epidemiology Public health Statins Cardiovascular disease (CVD) All-cause mortality Risk factors Smoking Uninsured patients Ethnic disparities |